<PAGE> SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 16, 1996 Date of Report (Date of earliest event reported) CELL THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) WASHINGTON 0-28386 91-1533912 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.) 201 Elliott Avenue, West Seattle, Washington 98119 (Address of principal executive offices, including zip code) (206) 282-7100 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS. NOTICE OF UNREGISTERED OFFERING On October 16, 1996 Cell Therapeutics, Inc. (the "Company") issued a press release under Securities and Exchange Commission Rule 135c giving notice of a second and final closing of $2,000,000 in an unregistered private offering of its Series A Convertible Preferred Stock, for an aggregate purchase price of $17,000,000. The text of that press release is included with this report as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits
<TABLE> <CAPTION> Exhibit No. Description ----------- ----------- <C> <S> 99.1 Press release dated October 16, 1996 issued under Securities and Exchange Commission Rule 135c giving notice of the closing of an unregistered offering of Series A Convertible Preferred Stock. </TABLE>
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELL THERAPEUTICS, INC. Dated: October 21, 1996 By /s/ JAMES A. BIANCO, M.D. ------------------------------------- James A. Bianco, M.D. President and Chief Executive Officer
<TABLE> <CAPTION> Exhibit No. Description Page No. - ----------- ----------- -------- <C> <S> <C> 99.1 Press release dated October 16, 1996 issued under Securities and Exchange Commission Rule 135c giving notice of the closing of an unregistered offering of Series A Convertible Preferred Stock. </TABLE>
<PAGE> [LETTERHEAD OF CTI] EXHIBIT 99.1 FOR IMMEDIATE RELEASE Contact: Lee M. Parker, Vice President Cell Therapeutics, Inc. 206/282-7100 firstname.lastname@example.org CELL THERAPEUTICS RAISES $2 MILLION IN SECOND TRANCHE OF PRIVATE PLACEMENT SEATTLE--October 16, 1996--Cell Therapeutics (cti) today announced the closing of a second and final tranche of $2 million in its company-managed private placement of $17 million in Series A Convertible Preferred Stock. Placed with existing institutional and accredited individual investors, these securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States without registration or applicable exemption from registration requirements. Cell Therapeutics, Inc. is a Seattle-based biopharmaceutical company focusing on the development of a new class of drugs that seeks to selectively regulate the metabolism of phospholipids in intracellular signaling pathways relevant to cancer and immune and inflammatory diseases. # # #